Adenoviral vectored vaccination protects against Crimean-Congo Haemorrhagic Fever disease in a lethal challenge model

Saunders, JE; Gilbride, C; Dowall, S; Morris, S; Ulaszewska, M; Spencer, AJ; Rayner, E; Graham, VA; Kennedy, E; Thomas, K; Hewson, R; Gilbert, SC; Belij-Rammerstorfer, S; Lambe, T

Journal article

Adenoviral vectored vaccination protects against Crimean-Congo Haemorrhagic Fever disease in a lethal challenge model

Abstract:: Background
The tick-borne bunyavirus, Crimean-Congo Haemorrhagic Fever virus (CCHFV), can cause severe febrile illness in humans and has a wide geographic range that continues to expand due to tick migration. Currently, there are no licensed vaccines against CCHFV for widespread usage.
Methods
In this study, we describe the preclinical assessment of a chimpanzee adenoviral vectored vaccine (ChAdOx2 CCHF) which encodes the glycoprotein precursor (GPC) from CCHFV.
Findings
We demonstrate here that vaccination with ChAdOx2 CCHF induces both a humoral and cellular immune response in mice and 100% protection in a lethal CCHF challenge model. Delivery of the adenoviral vaccine in a heterologous vaccine regimen with a Modified Vaccinia Ankara vaccine (MVA CCHF) induces the highest levels of CCHFV-specific cell-mediated and antibody responses in mice. Histopathological examination and viral load analysis of the tissues of ChAdOx2 CCHF immunised mice reveals an absence of both microscopic changes and viral antigen associated with CCHF infection, further demonstrating protection against disease.
Interpretation
There is the continued need for an effective vaccine against CCHFV to protect humans from lethal haemorrhagic disease. Our findings support further development of the ChAd platform expressing the CCHFV GPC to seek an effective vaccine against CCHFV.
Funding
This research was supported by funding from the Biotechnology and Biological Sciences Research Council (UKRI-BBSRC) [BB/R019991/1 and BB/T008784/1].

Publication status:: Published

Peer review status:: Peer reviewed

Actions

Email

Email this record

Send the bibliographic details of this record to your email address.

Your Email
Please enter the email address that the record information will be sent to.

-
Your message (optional)
Please add any additional information to be included within the email.
Share
Cite

Cite this record

APA Style

Saunders, J. E., Gilbride, C., Dowall, S., Morris, S., Ulaszewska, M., Spencer, A. J., Rayner, E., Graham, V. A., Kennedy, E., Thomas, K., Hewson, R., Gilbert, S. C., Belij-Rammerstorfer, S., & Lambe, T. (2023). Adenoviral vectored vaccination protects against Crimean-Congo Haemorrhagic Fever disease in a lethal challenge model. EBioMedicine, 90.

MLA Style

Saunders, JE, et al. “Adenoviral Vectored Vaccination Protects against Crimean-Congo Haemorrhagic Fever Disease in a Lethal Challenge Model.” EBioMedicine, vol. 90, 2023.

Chicago Style

Saunders, JE, C Gilbride, S Dowall, et al. 2023. “Adenoviral Vectored Vaccination Protects against Crimean-Congo Haemorrhagic Fever Disease in a Lethal Challenge Model.” EBioMedicine 90.
Print